Medpace Continues to Grow in Europe
News Aug 19, 2015
The new office is roughly three times the size of the former facility, allowing for significant growth in Data Management, Bio Statistics, Quality Assurance, Regulatory Affairs, Clinical Operations, and Safety. Together with the recently expanded London office, Medpace continues to invest in additional capacity for our operations globally. The UK offices in London and Stirling, Scotland, now houses close to 130 Medpace employees.
Medpace has focused expansion efforts in Europe over the past few years. The European activities have included adding additional clinical research professionals and expanding facilities in the United Kingdom, Poland, Russia, France, Germany and future significant office expansions planned for 2015/2016 in Leuven (Belgium), Prague (Czech Republic), Madrid (Spain). Medpace offices in Europe offer clinical operational support for a rapidly expanding Global and European market. Medpace established its first European office in the Czech Republic in 2005. Medpace employees in Europe now account for over one third of Medpace global employees.
With 12 European offices serving 30 EU countries, Medpace continues to grow and supply innovative support for studies in oncology, cardio metabolic, infectious disease, CNS, and other growing therapeutic areas. All European offices are fully integrated with Medpace global development services.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Key to Creating Better Medicines with Less Side EffectsNews
A new study published in Science by Professors Yossi Paltiel of the Hebrew University of Jerusalem and Ron Naaman from the Weizmann Institute of Science describes a breakthrough technology with the power to create drugs with fewer unwanted side effects.
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018